The Spanish drug regulator has approved a request by the Catalan-based pharmaceutical group Hipra to test a vaccine against COVID-19, which it is developing in at least 1,000 volunteers, Prime Minister Pedro Sanchez said today.
Hipra will conduct the so-called Phase 2 test – the second phase of a three-round test process – on volunteers at 10 hospitals across Spain, Sanchez said.
Speaking at an event on how the European Union recovery fund will be invested in health, Sanchez called the vaccine development “great news”.
“It shows that Spain can be at the forefront of the response to COVID,” he said, adding that the government had provided a 15m-euro grant to develop the drug.
Hipra, a pharmaceutical laboratory primarily engaged in the research and development of veterinary vaccines, is working on two COVID-19 vaccines.
One is based on the same mRNA technology used in vaccines developed by Pfizer and Moderna, while the second, which has just been licensed for testing, uses a recombinant protein such as that of Novavax, a US-based pharmaceutical company. .
Hipra said on its website that it predicts it will be able to produce 600 million doses in 2022 and double that number next year.
Source: AMPE
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.